Allogene Therapeutics, Inc. (ALLO) stock
ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.74−0.06 (-7.79%)
Close on Nov 17, 2026Market cap $257.08MP/E –Yield 0.00%
Allogene Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Allogene Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$102.20M. For fiscal 2025 it was -$149.25M. The highest annual figure on record is -$44.65M in fiscal 2018.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$149.25M | – |
| FY2024 | Dec 31, 2024 | -$200.30M | – |
| FY2023 | Dec 31, 2023 | -$237.73M | – |
| FY2022 | Dec 31, 2022 | -$220.52M | – |
| FY2021 | Dec 31, 2021 | -$184.81M | – |
| FY2020 | Dec 31, 2020 | -$115.09M | – |
| FY2019 | Dec 31, 2019 | -$137.35M | – |
| FY2018 | Dec 31, 2018 | -$44.65M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$32.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$12.91M | – |
| Q4 FY2025 | Dec 31, 2025 | -$27.60M | – |
| Q3 FY2025 | Sep 30, 2025 | -$29.69M | – |
| Q2 FY2025 | Jun 30, 2025 | -$39.03M | – |
| Q1 FY2025 | Mar 31, 2025 | -$52.93M | – |
| Q4 FY2024 | Dec 31, 2024 | -$36.70M | – |
| Q3 FY2024 | Sep 30, 2024 | -$44.12M | – |
| Q2 FY2024 | Jun 30, 2024 | -$63.59M | – |
| Q1 FY2024 | Mar 31, 2024 | -$55.90M | – |
| Q4 FY2023 | Dec 31, 2023 | -$53.71M | – |
| Q3 FY2023 | Sep 30, 2023 | -$55.53M | – |
| Q2 FY2023 | Jun 30, 2023 | -$61.86M | – |
| Q1 FY2023 | Mar 31, 2023 | -$66.64M | – |
| Q4 FY2022 | Dec 31, 2022 | -$62.10M | – |
| Q3 FY2022 | Sep 30, 2022 | -$47.66M | – |
| Q2 FY2022 | Jun 30, 2022 | -$42.53M | – |
| Q1 FY2022 | Mar 31, 2022 | -$68.24M | – |
| Q4 FY2021 | Dec 31, 2021 | -$45.44M | – |
| Q3 FY2021 | Sep 30, 2021 | -$48.88M | – |
| Q2 FY2021 | Jun 30, 2021 | -$41.17M | – |
| Q1 FY2021 | Mar 31, 2021 | -$49.33M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.98M | – |
| Q3 FY2020 | Sep 30, 2020 | -$37.59M | – |
| Q2 FY2020 | Jun 30, 2020 | -$26.72M | – |
| Q1 FY2020 | Mar 31, 2020 | -$40.81M | – |
| Q4 FY2019 | Dec 31, 2019 | -$50.27M | – |
| Q3 FY2019 | Sep 30, 2019 | -$31.94M | – |
| Q2 FY2019 | Jun 30, 2019 | -$24.89M | – |
| Q1 FY2019 | Mar 31, 2019 | -$30.26M | -605220.0% |
| Q4 FY2018 | Dec 31, 2018 | -$21.48M | – |
| Q3 FY2018 | Sep 30, 2018 | -$17.13M | – |
| Q2 FY2018 | Jun 30, 2018 | -$6.05M | – |
| Q1 FY2018 | Mar 31, 2018 | $5.00K | – |
See a number that looks wrong?